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Recent work with mouse models and human leukemic samples has shown that gain-of-function mutation(s)
in Notch1 is a common genetic event in T-cell acute lymphoblastic leukemia (T-ALL). The Notch1 receptor
signals through a -secretase-dependent process that releases intracellular Notch1 from the membrane to the
nucleus, where it forms part of a transcriptional activator complex. To identify Notch1 target genes in
leukemia, we developed mouse T-cell leukemic lines that express intracellular Notch1 in a doxycycline-
dependent manner. Using gene expression profiling and chromatin immunoprecipitation, we identified c-myc
as a novel, direct, and critical Notch1 target gene in T-cell leukemia. c-myc mRNA levels are increased in
primary mouse T-cell tumors that harbor Notch1 mutations, and Notch1 inhibition decreases c-myc mRNA
levels and inhibits leukemic cell growth. Retroviral expression of c-myc, like intracellular Notch1, rescues the
growth arrest and apoptosis associated with -secretase inhibitor treatment or Notch1 inhibition. Consistent
with these findings, retroviral insertional mutagenesis screening of our T-cell leukemia mouse model revealed
common insertions in either notch1 or c-myc genes. These studies define the Notch1 molecular signature in
mouse T-ALL and importantly provide mechanistic insight as to how Notch1 contributes to human T-ALL.
Mutations in the Notch1 receptor have been detected in
primary human T-cell acute lymphoblastic leukemia (T-ALL)
samples and cell lines and in several mouse models of T-ALL
(12, 26, 32, 36, 43). In human T-ALL, mutations are observed
in the heterodimerization (HD) and/or PEST regulatory do-
mains (43). In contrast to human T-ALL, HD mutations are
rare and insertions/frameshift mutations in the PEST region of
Notch1 predominate in mouse T-ALL models (12, 26, 32, 36).
Consistently, 74% of our spontaneous mouse tal1 tumors ex-
hibit high intracellular levels of Notch1 and evidence of sus-
tained Notch1 signaling (32). Upon inhibition of Notch1 sig-
naling, mouse tal1 leukemic cell lines undergo cell cycle arrest
and/or apoptosis, demonstrating that leukemic growth requires
a sustained, as-yet-undefined Notch1 signal. Taken together,
these studies reveal that Notch1 activation is a common and
critical event in T-ALL and raise the possibility that Notch1
pathway inhibitors may have efficacy in the treatment of T-
ALL (12, 26, 32, 36, 43).
Upon ligand binding, the highly conserved Notch1 trans-
membrane receptor undergoes two successive proteolytic
cleavages that result in the translocation of the intracellular
domain of Notch1 (Notch1IC) to the nucleus (10). Within the
nucleus, Notch1IC binds to and displaces the corepressors from
CSL/RBP-J [also known as CBF1, Su(H), or Lag-1], thereby
relieving transcriptional repression (24, 34). Notch1IC then
recruits a member of the Mastermind (MAM) family and other
transcriptional activators, such as CBP/p300, GCN5, and
PCAF, to activate transcription of target genes such as hes1,
deltex, and pre-T (8, 24, 34). CycC–cyclin-dependent kinase 8
(CDK8) and CycT1–CDK9/p-TEFb are also found recruited to
the Notch1 target gene promoters, and recent work suggests
that MAM not only functions in transcriptional activation but
also regulates Notch1IC turnover by facilitating CycC:CDK8
phosphorylation of the C-terminal PEST domain of Notch1
(15, 16, 42). Notch1IC phosphorylation by CycC:CDK8 (16)
and potentially other kinases promotes PEST recognition and
subsequent degradation by the E3 ubiquitin ligases Numb,
Fbw7/Sel10, and Itch (28, 35, 41).
Although clearly implicated in the etiology and pathogenesis of
mouse and human T-ALL, the precise molecular nature of the
Notch1 signal(s) in T-cell leukemogenesis remains unknown. Pre-
vious studies of other cell types have implicated Notch1 in the
regulation of cyclin D1 and the cell cycle inhibitor p21 (30, 37).
Inducible expression of Notch1 has been shown to enhance the
expression of c-myc during the culture of mouse hematopoietic
progenitors. Reporter assays and electrophoretic mobility shift
assay analysis narrowed the Notch1 responsive region within the
mouse c-myc promoter; however, the region defined did not con-
tain a typical RBP-J (or CSL) binding sequence, and antibodies to
the transfected FLAG-RBJ-VP16 fusion protein failed to super-
shift the complex, leading the authors to conclude that the acti-
vation of c-myc by Notch1 may be indirect (38).
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To specifically identify Notch1IC target genes in mouse T-
cell leukemia, we developed doxycycline (Dox)-regulated
Notch1IC T-ALL cell lines. To generate these leukemic cell
lines, we isolated thymomas from a doxycycline-regulatable
intracellular Notch1 transgenic mouse (4). Administration of
Dox to these leukemic animals inhibited Notch1IC expression
and caused rapid tumor regression by induction of apoptosis
(4). Similar to what was observed in vivo, addition of doxycy-
cline to the culture medium suppressed Notch1IC expression
and caused the leukemic cells to undergo G1 arrest and apop-
tosis, directly demonstrating the requirement for Notch1, op-
posed to other -secretase-dependent proteins, in leukemic
growth/survival. We then used gene expression profiling to
reveal the Notch1 signature in mouse T-cell leukemia. Consis-
tent with published work, several known Notch1 target genes
and pathways were induced. Microarray analyses and chroma-
tin immunoprecipitation (ChIP) studies identified c-myc as a
direct Notch1 target gene in mouse leukemic cells. Impor-
tantly, we demonstrate the functional consequences of Notch1
inhibition and identify c-myc as a critical Notch1 target gene in
Notch1-mediated leukemogenesis. Consistent with these find-
ings, retroviral insertional mutagenesis (RIM) screening of our
tal1 leukemic mouse model reveals common insertions in
notch1 or c-myc genes. These studies define the Notch1 mo-
lecular signature in mouse T-ALL and importantly provide
mechanistic insight into how Notch1 contributes to T-cell leu-
kemia.
MATERIALS AND METHODS
Mice and T-ALL cell lines. For the RIM screen, wild-type or mut tal1 (R188G;
R189G) neonates were injected with 50 l of Moloney murine leukemia virus
(MoMLV) and monitored daily for signs of disease. Kaplan-Meier analysis was
performed on MoMLV-infected mut tal1 mice compared to uninfected mut tal1
mice. To develop a Dox-regulated NotchIC T-ALL line, a cohort of E/tTA/
notchIC mice (4) were aged and monitored for disease. To convert primary
tumors to culture, E/tTA/notchIC tumors were minced into a single-cell suspen-
sion using frosted slides and cultured in RPMI with 10% fetal bovine serum, l%
glutamine, penicillin/streptomycin, and 50 M -mercaptoethanol. Primary tu-
mor cells were plated at three concentrations in a six-well plate: 5  106, 1 107,
and 2  107 cells per well. Tumor cells were left undisturbed for 1 week and
subsequently fed three times weekly by careful aspiration and addition of fresh
medium. When nonadherent cells became confluent, they were transitioned to a
60-mm dish and finally to a 10-cm dish.
IPCR and Southern blot analysis. Genomic DNA was isolated from MoMLV-
infected mut tal1/scl (R188G;R189G) tumors. One microgram of DNA was di-
gested overnight with PstI, heat inactivated, and ligated in a total volume of 600
l overnight at 16°C. The ligation was ethanol precipitated and digested with
ClaI. Following the ClaI digest, inverse PCR (IPCR) was performed using the
Long Template Expand kit (Roche, Indianapolis, IN) and primers to MoMLV
long terminal repeat (5CTTGTGGTCTCGCTGTTCCTT3) and to the region
adjacent to the PstI site within MoMLV (5TTAAGCTAGCTTGCCAAACCT
ACAGGT3). PCR products were electrophoresed on a 1% agarose gel, ex-
tracted, cloned into pCR4-TOPO (Invitrogen, Carlsbad, CA), and sequenced.
Genomic DNA was extracted from MoMLV-infected tal1/scl tumors and un-
infected tal1/scl tumors. Fifteen micrograms was digested overnight with EcoRV
(notch1 cluster region I) or Asp718 (notch1 cluster region II), electrophoresed on
a 0.8% agarose–1 Tris-borate-EDTA gel, and transferred to a nylon mem-
brane. The membrane was then probed with a cDNA probe corresponding to
Notch1 cluster region I or cluster region II as in reference 13.
Western blot analysis. Protein was isolated from MoMLV-infected tumors
and wild-type thymocytes using radioimmunoprecipitation assay (RIPA) buffer
containing protease inhibitor tablets (Roche). Fifty micrograms of total protein
was resolved on a 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) gel, transferred to a nitrocellulose membrane, and probed with
polyclonal antibodies against intracellular Notch1 or with an antibody specific for
Notch1 activated by cleavage at Val 1744 (#2421; Cell Signaling Technology).
Blots were stripped and reprobed with -actin (A5441; Sigma, St. Louis, MO) to
control for equal loading.
Flow cytometry. The NotchIC T-ALL 3404 cell line was cultured with doxycy-
cline (2 g/ml) for the time periods indicated in the text; stained with CD25-
phycoerythrin (PE) conjugate, CD4-fluorescein isothiocyanate (FITC), or
CD8-PE (Pharmingen); and analyzed by flow cytometry. For cell cycle analysis,
the cells were fixed in 70% ethanol, stained with propidium iodide (PI), and
analyzed for DNA content.
Microarray analysis. The Dox-regulated NotchIC T-ALL cell line was treated
with doxycycline (2 g/ml) for 24 h, and RNA was extracted using Trizol
reagent (Invitrogen, Carlsbad, CA), purified using a QIAGEN RNeasy Mini kit
(QIAGEN, Valencia, CA), and hybridized to Affymetrix mouse genome 430A2.0
arrays (Affymetrix, Santa Clara, CA). The experiment was performed in tripli-
cate to minimize artifacts. The normalization was performed using the D-chip,
and the expression level was modeled using the perfect-match-only model. The
probe sets absent in 50% of the arrays of either group were not included in the
analysis. The set of differentially expressed genes was determined on the basis of
an unpaired Student’s t test. All genes with a 	1. 5-fold change and a P value of

0.05 were considered to show significant differential expression. For the hier-
archical clustering, the top probes showing more than a twofold change and P
value of 
0.05 were used. A total of 59 unique genes were identified from 81
probe sets. The interaction networks between the genes showing significant
differential expression (Fc 	 1.5 and P 
 0.05) were generated using the web-
based interactive package Ingenuity Systems. This analysis results in identifica-
tion of networks that are differentially perturbed between the two groups.
RNA analyses. RNA was extracted from MoMLV-infected tal1/scl tumors,
tal1/scl tumors, wild-type thymocytes, and tal1/scl thymocytes using Trizol. cDNA
was synthesized using the Superscript first-strand synthesis system (Invitrogen).
deltex, hes1, and pre-T expression was assayed using primers as described in
reference 9. Specific c-myc primers were designed using Primer Express software
(Applied Biosystems): forward, 5-CTGTTTGAAGGCTGGATTTCCT-3; re-
verse, 5-CAGCACCGACAGACGCC-3. To determine c-myc expression levels,
cDNA was serially diluted and quantitated using the SYBR green kit (QIAGEN)
containing the c-myc-specific primers and -actin-specific primers. The copy
number for c-myc was normalized to the copy number for -actin.
ChIP assay. Approximately 108 cells were resuspended in cold phosphate-
buffered saline solution containing 1% formaldehyde and incubated for 10 min
at 4°C with continuous shaking. After 10 min, the cross-linking was reversed by
adding glycine to a final concentration of 0.125 M and incubating the cells at 4°C
for 5 min with continuous shaking. Cells were then harvested and washed twice
with ice-cold phosphate-buffered saline. Nuclei were isolated by incubating the
cells in nucleus isolation buffer {5 mM PIPES [piperazine-N,N-bis(2-ethanesul-
fonic acid)], pH 8.0, 85 mM KCl, 0. 5% NP40} for 20 to 30 min on ice. The nuclei
were harvested at 4°C by centrifuging the cell suspension at 6,000 rpm for 6 min.
The nuclei were resuspended in 1. 5 ml of RIPA buffer (150 mM NaCl, 1%
[vol/vol] Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris [pH
8. 0], 5 mM EDTA) containing protease inhibitors. Nuclear lysates were soni-
cated to yield chromatin fragments of approximately100 to 700 bp as assessed by
agarose gel electrophoresis. Nuclear debris was removed by centrifuging the
lysates at 4°C for 15 min at 14,000 rpm. Nuclear extracts were precleared by
incubation with the protein A Sepharose CL-4B beads (Pharmacia) for 30 min
with rocking at 4°C. After centrifugation for 2 min at 3,000 rpm at 4°C, the
supernatants were transferred to a new tube. Immunoprecipitation was per-
formed by rocking the extracts overnight at 4°C with the respective antibody.
Protein A Sepharose CL-4B beads were added, and the immunocomplexes were
allowed to bind to the beads for 2 h at 4°C with rocking. Immunocomplexes
bound to beads were then washed once each with RIPA buffer, RIPA buffer
containing 500 mM NaCl, and immunoprecipitation wash buffer (10 mM Tris Cl
[pH 8.0], 250 mM LiCl, 0. 5% NP40, 0. 5% deoxycholate, 1 mM EDTA) and once
with Tris-EDTA. Between washes, samples were rocked end over end for 5 min.
Beads were resuspended in 300 l of elution buffer (50 mM Tris Cl, pH 8.0, 10
mM EDTA, 1% SDS) followed by overnight incubation at 55°C. DNA was
phenol-chloroform extracted, ethanol precipitated, allowed to air dry, and finally
dissolved in sterile water. Immunoprecipitated DNAs for acetylated histones H3
and H4 were diluted sixfold and threefold, respectively, to keep the PCR in the
linear range of amplification. The following set of primers was used to amplify
different regions of the genes indicated: for the promoter region of c-myc,
5-GGAAACTGGGAAATTAATGTA-3 (forward) and 5-TTCCCAGAAAG
GGGGAGGAGTGA-3 (reverse); for the TATA region of c-myc, 5-ACTAG
CGCGCGAGCAAGAGAAAA-3 (forward) and 5-GGGATTAGCCAGAGA
ATCTCTCT-3 (reverse); and for the hes1 promoter region, 5-GACCTTGTG
CCTAGCGGCCA-3 (forward) and 5-TCTGTCCCCTAAGGCGACAA-3
(reverse).
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RESULTS
The notch1 locus is a common retroviral insertion site in a
tal1 transgenic mouse model of T-ALL. Transgenic mice ex-
pressing Tal1 or a DNA-binding mutant Tal1 (mut tal1) de-
velop T-cell acute lymphoblastic leukemia after a long latency,
indicating that additional genetic events are required to induce
leukemia (21, 31). Both tal1 models induce T-cell leukemia
primarily by interfering with E47/HEB function (31, 33). To
identify cooperating oncogenes in this T-cell leukemia mouse
model, we performed RIM. Wild-type or mut tal1 transgenic
neonates were injected with MoMLV. As expected, infection
with MoMLV greatly accelerates the rate of disease, with a
median survival latency of 81 days for the infected mut tal1
transgenic mice compared to 215 days for uninfected mut tal1
mice (Fig. 1A). In addition, MoMLV-infected mut tal1 mice
develop leukemia with complete penetrance. As expected,
MoMLV-infected wild-type FVB/N mice also develop disease,
but with a significantly longer latency than MoMLV-infected
mut tal1 transgenic mice (data not shown). We utilized IPCR
to clone the region adjacent to the MoMLV integration in the
genome. We determined that the MoMLV provirus integrated
into intron 28 of the notch1 gene, which likely results in ex-
pression of a constitutively active intracellular Notch1 protein.
To determine the frequency of notch1 integrations in MoMLV-
infected mut tal1 tumors, we performed Southern blot screen-
ing on the remaining MoMLV-infected tumors. We digested
genomic DNA from MoMLV-infected mut tal1 tumors with
EcoRV, transferred it to a membrane, and probed it with
notch1 cDNA probes. The probe contains notch1 cDNA exons
22 to 26 or cluster region I, which has previously been shown
to be a common site of integration in MMTVD/myc and E2A/
Pbx1 transgenic mice (13, 17). Thirty-two percent (8/25) of the
MoMLV-infected mut tal1 tumors contained integrations in
the notch1 locus (data not shown and Fig. 1B). Surprisingly,
additional Southern blot screening failed to detect MoMLV
integrations in the 3 cluster region II, which encompasses the
regulatory PEST domain (Fig. 1B). Previous studies have
shown that Notch1 can cooperate with the expression of dom-
inant-negative isoforms of Ikaros, and these forms of Ikaros
are also detected in human T-ALL (3, 6, 40).
To determine if the integration of MoMLV into the notch1
allele increased intracellular Notch1 levels, we performed
Western blot analysis of MoMLV-infected mut tal1 tumors
(Fig. 1C). Tumors that contain notch1 integrations (no. 699
and 676) display increased levels of Notch1IC compared to
wild-type thymocytes or MoMLV-infected tumors without
Notch1 integrations (no. 692 and 732). To further determine if
the Notch1 pathway was activated in these tumors, we exam-
FIG. 1. Notch1 activation in MoMLV-infected mut tal1 tumors. (A) Disease acceleration in MoMLV-infected mut tal1 transgenic mice. Shown
is a Kaplan-Meier survival plot of MoMLV-infected tal1/scl transgenic mice. The cohort of tal1/scl transgenic mice consisted of 62 mice, and the
cohort of infected mice consisted of 27 mice. (B) The notch1 locus is a common integration site in infected tumors. Genomic DNA from
MoMLV-infected tumors (1359, 1364, 1438, 1349.1, 1349.2, 1349.3, 675, and 676) and from two uninfected tal1 tumors was digested with EcoRV
and hybridized with a probe to cluster region I of Notch1 (13). (C) Notch1 activation in MoMLV-infected tumors. Lysates from tumors with
MoMLV integrations in notch1 (699, 676, and 4830) were probed with an anti-Notch1 (-Notch1) antibody and compared to lysates from infected
tal1 tumors with no detectable Notch1 integrations (692 and 732) or from wild-type thymus (wt thy). (D) Hes1 and Deltex are expressed in tumors
with MoMLV insertions in Notch1. hes1 and deltex expression was examined in wild-type and preleukemic tal1 thymocytes and MoMLV-infected
tumors with insertions in Notch1 using RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase (gapdh) was used as an internal control.
8024 SHARMA ET AL. MOL. CELL. BIOL.
 o
n
 O
ctober 17, 2012 by UNIV O
F M
ASS M
ED SCH
http://m
cb.asm
.org/
D
ow
nloaded from
 
ined expression of known Notch1 target genes, hes1 and deltex,
using reverse transcription-PCR (RT-PCR). Compared to
wild-type thymocytes, MoMLV-infected mut tal1 tumors ex-
hibit increased levels of hes1 and deltex expression, suggesting
that the Notch1 pathway is constitutively active in the infected
mut tal1 tumors (Fig. 1D). Insertions were also frequently
observed in the c-myc locus (6/25) (Table 1). Of the 14 tumors
with insertions in notch1 or c-myc, only one tumor (no. 4830)
contained proviral insertions in both notch1 and c-myc. The
remaining 13/14 tumors contained retroviral insertions in ei-
ther notch1 or c-myc, suggesting that Notch1 or c-Myc ac-
tivation can cooperate with tal1 to induce leukemia in mice
(Table 1).
Effects of GSI treatment on mouse tal1 leukemic cell lines
and primary tal1 tumor tissue. The high frequency of MoMLV
integrations in notch1 in the tumors derived from MoMLV-
infected tal1 mice prompted us to test whether activating
notch1 mutations could be detected in the DNA isolated from
spontaneous, primary mouse tal1 tumors. As the RIM screen
predicted, we found a high frequency (20/27 [74%]) of muta-
tions that create frameshifts or introduce premature stop
codons, resulting in truncations in the PEST domain of
Notch1, whereas mutations in the heterodimerization domains
of Notch1 were rarely detected (32).
In vitro studies using GSI to inhibit Notch1 have shown that
human T-ALL cell lines remain dependent on Notch1 signal-
ing for their growth and survival (43, 44). Interestingly, -secre-
tase inhibitor (GSI) treatment of human T-ALL cell lines
results in predominantly G1 arrest, and a minority of human
T-ALL lines exhibit apoptosis (43). In contrast, treatment of
mouse tal1 tumor lines with GSI predominantly results in in-
creases in sub-G1 cells without evidence of G1 arrest (32) (Fig.
2A). The reason for the difference in responses to GSI treat-
ment between human and mouse T-ALL cell lines is unclear.
One possibility might be that G1 arrest precedes accumulation
in sub-G1. To examine this, we treated mouse T-ALL lines
having Notch1 mutations with GSI and examined the cell cycle
profiles at earlier time points. GSI treatment of mouse tal1
lines 720 and 130 for 3 days reveals induction of G1 arrest and
an increase in sub-G1 cells (Fig. 2A) (data not shown). GSI
FIG. 2. GSI treatment induces G0/G1 arrest followed by apoptosis,
and leukemic growth is rescued by expression of intracellular Notch1.
(A) G0/G1 arrest precedes the accumulation of sub-G1 cells. Mouse
T-ALL cell line 130 with Notch1 PEST truncation was treated with
DMSO or 1 M N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylgly-
cine t-butyl ester (DAPT) for 3 or 6 days, and cells were assayed for
DNA content by staining with PI. (B). GSI treatment of primary tal1
tumor tissue induces apoptosis. Primary thymic masses isolated di-
rectly from the animal were left untreated or were treated with 1 M
GSI. Three days later, cells were stained with FITC-Annexin V/PI and
analyzed by flow cytometry. (C) GSI-induced effects in mouse T-ALL
cells are rescued by human intracellular NOTCH1 (ICNX) expression.
Mouse T-ALL line 720 was left uninfected or was infected with vector
only or with a retrovirus that expresses human intracellular NOTCH1
(ICNX) and then was left untreated or was treated with 1 M GSI
(MRK-003) for 3 days, and the percentage of viable cells was deter-
mined by trypan blue exclusion. The rescue assay was repeated a
minimum of three times. A representative experiment is shown.
TABLE 1. MoMLV-infected tal1 tumors harbor proviral
integrations in notch1 or c-myc
MoMLV tumor
Presence of integration ina:
Notch c-Myc
1349.2  
1349.3  
1359  
1364  
676  
731  
699  
4830  
702  
105  
4819  
4820  
4823  
4829  
a , integration present; , integration absent.
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treatment of mouse leukemic line 130 results in a 21% increase
in the percentage of leukemic cells in G0/G1 phase. A concom-
itant 14% increase in sub-G1 cells was also observed in the
GSI-treated cultures (Fig. 2A). By 6 days of GSI treatment,
there was a 10-fold increase in sub-G1 cells, with 45% of the
cells in the sub-G1 fraction. Similar results were obtained with
tal1 leukemic line 720 (data not shown). These studies reveal
that in the tal1 cell lines examined, GSI treatment results in an
initial G1 arrest followed by an accumulation of sub-G1 cells,
suggesting that Notch1 is required for leukemic growth.
These in vitro studies suggest that GSI may have efficacy in
vivo; however, cell line sensitivity may not reflect primary tu-
mor response in vivo, and therefore it is important to demon-
strate GSI efficacy against primary tumor tissue. Primary thy-
mic masses were isolated directly from diseased tal1 transgenic
mice and exposed to carrier (dimethyl sulfoxide [DMSO]) or
GSI for 3 days. The tumor tissue exhibited variable amounts of
background apoptosis upon placement in culture. The addition
of GSI to these primary cultures resulted in significant increase
in apoptotic cells, as detected by FITC-annexin V/PI staining
(Fig. 2B; average increase of 51% apoptotic cells in the GSI-
treated primary cultures).
The GSI-induced apoptosis of primary tal1 thymic masses
suggests that GSI may have efficacy in vivo in mouse models of
T-ALL and, most importantly, in patients. However, the pos-
sibility exists that the apoptosis observed in GSI-treated mouse
tal1 tumor cell lines and tumor tissue may be in part mediated
by inhibition of other -secretase-dependent pathways. To rule
out this possibility and demonstrate that T-cell leukemic lines
and tumor tissue were dependent on Notch1 for growth, we
tested whether intracellular Notch1 expression can rescue the
GSI-induced apoptosis in multiple mouse tal1 tumor lines.
Mouse tal1 tumor lines were left uninfected or were infected
with murine stem cell virus (MSCV) retroviral vector only or
with a retrovirus that expresses intracellular NOTCH1 (ICNX),
and the cultures were treated with either DMSO or GSI. Fol-
lowing 3 days of culture with the GSI, 80% of the uninfected or
MSCV-infected cultures had undergone apoptosis (Fig. 2C).
Retroviral expression of ICNX prevented the GSI-induced
apoptosis, demonstrating that inhibition of the Notch1 path-
way is responsible for the effects on leukemic growth.
Development of conditional Notch1IC T-ALL line. The crit-
ical signal(s) Notch1 activation provides during leukemogene-
sis remains unknown. To elucidate how Notch1 contributes to
leukemogenesis and to specifically regulate Notch1IC expres-
sion, we developed a Dox-regulated Notch1IC leukemic cell
line. To develop this system, we isolated tumors arising in
E/tTA/NotchIC transgenic mice (4) and adapted them to cul-
ture. Of 14 tumors isolated, only three tumor lines successfully
converted to culture, and one of the three remained responsive
to doxycycline. Western blot analysis of the Dox-regulated
NotchIC T-ALL line demonstrates that following Dox treat-
ment for 24 h, Notch1IC levels decrease to levels seen in wild-
type thymocytes (Fig. 3A). To confirm the Notch1IC signaling
pathway was intact in this cell line and functioning in a Dox-
dependent manner, we performed RT-PCR and assayed hes1
and deltex expression levels following Dox treatment. We ob-
served a significant reduction in hes1 and deltex expression
levels following 18 h of Dox treatment and failed to detect any
hes1 or deltex expression following 24 h of Dox treatment (Fig.
3B). Decreases in pre-T expression were also observed fol-
lowing Dox treatment or Notch1IC repression, indicating that
the expression of known Notch1 target genes in T cells was also
affected.
G1 arrest and apoptosis upon Notch1 inhibition. To test
whether Notch1IC provides an essential proliferative/survival
signal(s), we performed cell cycle analysis in the presence and
absence of doxycycline. Forty-eight hours following Dox treat-
ment, there was an increase in cells in G1 phase (35.6% to
48%) but no significant change in the percentage of sub-G1
cells (Fig. 3C). However, following 72 h of Dox treatment,
there was a statistically significant increase in cells in the
sub-G1 phase of the cell cycle (15% to 45.3%), indicating an
FIG. 3. A conditional Notch1IC mouse T-ALL cell line. (A) Dox
administration represses Notch1IC expression. Fifty micrograms of
protein isolated from wild-type thymocytes and doxycycline-regulated
T-ALL cell line 3404 was left untreated or was treated with 2 g/ml
Dox. Cell lysates were separated on a 7. 5% SDS-PAGE gel and then
probed with anti-Notch1 (-Notch1) antibody. (B) Decreased hes1,
deltex, and pre-T expression upon the addition of Dox. Expression of
hes1, deltex, and pre-T in the Dox-regulated NotchIC T-ALL line was
examined by RT-PCR following mock treatment or doxycycline (2
g/ml) treatment for the time periods indicated. Glyceraldehyde-3-
phosphate dehydrogenase (gapdh) was used as an internal control.
(C) Dox treatment or Notch1IC inhibition induces G0/G1 arrest fol-
lowed by an increase in sub-G1 cells. Following 48 or 72 h of doxycy-
cline treatment, cells were assayed for DNA content by staining with
PI. Similar to GSI treatment of mouse T-ALL lines, Dox treatment of
3404 cells induces G0/G1 arrest followed by an increase in sub-G1 cells.
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increase in cells undergoing apoptosis (P  0.0009) (Fig. 3C).
In addition, when the sub-G1 cells were removed, a 22% in-
crease in cells in G0/G1 phase of the cell cycle was observed
(P 
 0.002; data not shown), demonstrating that Notch1IC in
this cell system provides an essential proliferative signal, sim-
ilar to what has been observed when GSI are added to human
and mouse T-ALL cell cultures (32, 43).
Notch1 target genes in T-ALL. To determine how NotchIC
stimulates T-cell proliferation during leukemogenesis, we per-
formed an Affymetrix microarray experiment comparing gene
expression profiles in the Notch1IC T-ALL line in the absence
of Dox and following a 24-h Dox treatment to suppress
Notch1. The systematic analysis of the gene expression data (as
explained in Materials and Methods) resulted in the identifi-
cation of a set of differentially expressed genes (Fc 	 1.5 and
P 
 0.05). As expected, in the presence of continuous expres-
sion of Notch1IC, many known Notch1 target genes were in-
duced, including hes1, deltex, il-2r, and pre-T (1, 9) (Fig. 4).
In addition, multiple genes implicated in Notch1 signaling
were also found to be upregulated in the absence of doxycy-
cline: for example, notch3, adam19 (meltrin ), and members
of the interferon 200 gene family (ifi202b) (Fig. 4) (1, 9, 20).
The array data show an increase in interleukin-10 (IL-10) levels;
IL-10 is known to be upregulated following Notch1IC activation
by Jagged1 (2).
Expression of Notch1IC in this Dox-regulated T-ALL cell
line appears to induce multiple genes implicated in regulation
of Notch1 signaling. For example, deltex is highly expressed in
the absence of doxycycline and has been proposed to antago-
nize or promote Notch1 function, depending on the model
system (2, 27). In addition, Notch1IC induces expression of
both nr2f2 (nuclear receptor subfamily 2, group F, member 2)
and nrarp (Notch-regulated ankyrin repeat protein). Nrarp has
been shown to inhibit Notch function in a CSL-dependent
manner and is also capable of inhibiting thymocyte develop-
ment in vivo (23, 45). As suggested by previous studies,
Notch1IC induces the expression of genes that negatively reg-
ulate its transcriptional activity or function.
Notch1 directly regulates c-myc expression. To interpret the
gene expression data, a network-based analysis of the differ-
entially expressed genes (360 genes) was performed using the
trial version of Ingenuity Systems. The analysis identified many
networks with significant interactions, including the gamma
interferon (IFN-) pathway. Out of these, a network depicting
c-myc as a potential Notch1-regulated gene was found to be
primarily stimulated (Fig. 4). Real-time PCR analysis con-
firmed that c-myc expression was doxycycline or Notch1 de-
pendent in the conditional NotchIC leukemic cell line. In the
absence of Dox, an average 3.2-fold increase in c-myc expres-
sion was observed. Moreover, the expression of 35 known
FIG. 4. Notch1-regulated genes in mouse T-ALL. Shown is a heat
map of clustered samples in columns and clustered genes in rows of
expression data of mouse leukemic cell line 3404 cultured in the
presence or absence of doxycycline or Notch1IC. The pseudocolor
representation of gene expression ratios is shown with the scale below.
The hierarchical clustering was performed for genes having a change
of more than twofold (P value of 0.005). NotchIC target genes are
indicated by ; c-myc target genes are indicated by an asterisk.
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c-Myc target genes was also affected (Fig. 4; genes noted with
asterisks).
These studies suggest that Notch1 promotes leukemic
growth by sustaining c-myc mRNA levels. Consistently, we
found c-myc mRNA levels increased between 9- and 23-fold in
primary tal1 tumors that harbor mutations in Notch1 (Fig. 5A).
To determine whether increased c-myc mRNA levels reflect
increased Notch1 activity, we quantified c-myc mRNA levels in
the presence/absence of GSI. GSI treatment resulted in three-
to fourfold decreases in c-myc mRNA levels, yet c-myc mRNA
levels were maintained in leukemic cells expressing human
intracellular Notch1, even in the presence of GSI (Fig. 5B).
Collectively, these data demonstrate that Notch1 activity reg-
ulates c-myc expression in mouse leukemic T cells. Interest-
ingly, we found hes1, deltex, and c-myc mRNA levels all in-
creased in preleukemic tal1 thymocytes (39), suggesting that
Notch1 activation and c-myc deregulation may be early events
in T-cell leukemogenesis.
To test whether enforced c-myc expression rescues the GSI-
induced growth arrest and apoptosis, we infected two Notch1-
dependent mouse tal1 cell lines, 720 and 130, that express
mutated forms of Notch1 lacking an intact PEST domain.
Leukemic cell lines were left uninfected or were infected with
MSCV or with retroviruses expressing either intracellular
NOTCH1 (ICNX) or c-myc. Following 6 days of GSI treat-
ment, 80% of 720 cells had undergone apoptosis (Fig. 2A and
5B). Retroviral expression of c-myc prevented the GSI-induced
apoptosis and promoted growth to a similar extent as the
expression of intracellular Notch1 (ICNX), suggesting that sus-
tained activation of c-myc is one major target of Notch1 in
T-ALL.
The kinetics of c-myc expression in the Notch1-regulated
leukemic cell line and the presence of conserved, tandem CSL
binding sites in the regulatory regions of mouse and human
c-myc suggest that c-myc may be directly regulated by Notch1.
To address whether Notch1 regulates c-myc expression di-
rectly, we examined Notch1IC recruitment to c-myc regulatory
regions using a ChIP assay. Previous work has demonstrated
Notch1 recruitment to the hes1 promoter (16); we therefore
used hes1 as a positive control for our ChIP assays. Consistent
with these published studies, we observed Dox-dependent re-
cruitment of intracellular Notch1 and its coactivator, MAM, to
the mouse hes1 promoter region in our leukemic cell line (Fig.
6A). Consistent with the induction of hes1 expression in the
absence of Dox (presence of Notch1IC), we observed recruit-
ment of RNA polymerase II/CDK9 and increases in histone
H3 and H4 acetylation (Fig. 6A). Similarly, in the absence of
Dox, we found intracellular Notch1 recruited to the mouse
c-myc promoter region (Fig. 6B and C). To test whether
Notch1IC recruitment correlated with changes in c-myc tran-
scriptional activity, we compared the acetylated histone H3
and H4 binding as well as RNA polymerase II recruitment to
the mouse c-myc promoter in the presence and absence of
Dox. In the absence of Dox and the presence of intracellular
Notch1, increases in acetylated histones H3 and H4 and RNA
polymerase II recruitment were consistently observed, indicat-
ing that c-myc can be directly regulated by intracellular
Notch1. Whereas when the expression of Notch1IC was inhib-
ited by Dox, decreased binding of Notch1IC, MAM, RNA
polymerase II, and CDK9 was observed. The Dox-mediated
FIG. 5. Leukemic growth is Notch1 and c-myc dependent. (A) c-myc
expression is increased in primary tal1 tumors that contain mutations in
Notch1. c-myc RNA levels were examined using real-time PCR in three
primary tal1 tumors with insertions/deletions in the PEST region of
Notch1. (B) GSI treatment results in downregulation of c-myc mRNA
levels, whereas c-myc levels are maintained in leukemic cells infected with
an intracellular Notch1 retrovirus. c-Myc RNA levels were measured
using real-time PCR. RNA was harvested from the leukemic cell line 720
treated with DMSO or 1 M N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-
phenylglycine t-butyl ester (DAPT) and from 720 cells that were infected
with MSCV or with a human ICNX retrovirus treated with DMSO or 1
M DAPT. c-Myc levels were quantified using a real-time PCR assay.
(C) Leukemic growth is rescued by c-Myc or intracellular Notch1 expres-
sion. Multiple mouse leukemic cell lines were left uninfected or were
infected with MSCV or with retroviruses expressing either human intra-
cellular NOTCH1 (ICNX) or mouse c-myc. Cultures were treated with
either DMSO or DAPT (1 m) for 6 days, and viable cells were deter-
mined by trypan blue staining. The experiment was repeated at least three
times, and one representative experiment is shown.
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suppression of Notch1IC expression was also accompanied by
decreases in histone H3 and H4 acetylation at the c-myc reg-
ulatory regions (Fig. 6B and C). None of these interactions
were observed in the absence of specific antisera, and none of
these proteins bound mouse c-myc in a 3 intergenic region
downstream of the polyadenylation site (data not shown). In
sum, the Dox-induced growth arrest and apoptosis were coin-
cident with the depletion of the Notch1IC/MAM transcrip-
tional complex from c-myc regulatory regions and with de-
creases in c-myc expression. Considered together, these studies
strongly suggest that Notch1 contributes to T-cell leukemogen-
esis by directly regulating the expression of c-myc.
DISCUSSION
Retroviral insertional mutagenesis revealed that the T-cell
oncogene tal1 cooperates with activated Notch1 to induce T-
ALL in mice. The notch1 proviral integrations occurred in
cluster region I, which contains the LIN-12/Notch repeat
(LNR) and epidermal growth factor-like repeat (EGFR) mo-
tifs. Conversely, no integrations were detected in cluster region
II, located within the 3 regulatory regions that contain the
PEST domain. Previous RIM screens of both E2A-Pbx1 and
MMTVD/myc transgenic mice detected MoMLV integrations
in the 3 region of notch1, and these were shown to cooperate
with the initiating oncogene to cause disease (13, 17). It is
unclear why spontaneous tal1 tumors appear to preferentially
truncate the PEST domain (32), whereas analysis of MoMLV-
infected tal1 tumors detected integrations in the midregion of
notch1 and no 3 integrations were detected. One possibility is
that too few tumors were examined in the RIM screen (n 25)
and that with larger screens, 3 integrations in notch1 would
also be observed. Nonetheless, this screen revealed that in-
creases in Notch1 signaling contribute to mouse T-ALL and
prompted us to investigate the status of the Notch1 receptor in
spontaneous Tal1 mouse tumors. That analysis revealed that
mouse tal1 tumors harbor truncated versions of intracellular
Notch1 that delete the PEST regulatory region (32).
To understand how Notch1 mutations contribute to T-cell
leukemia, we developed a mouse leukemic line that expresses
Notch1IC in a Dox-dependent manner. The conditional Notch1IC
T-ALL line provides multiple advantages over other experi-
mental systems to examine the function of Notch1 in leuke-
mogenesis. Although GSI are commonly used to inhibit the
cleavage and activation of Notch receptors (8), they do not
specifically inhibit Notch1 but also inhibit cleavage of a num-
ber of other transmembrane proteins (7, 18, 25, 29). Moreover,
the response of human and mouse leukemic cell lines to GSI is
not uniform: sensitive cell lines undergo variable amounts of
cell cycle arrest/apoptosis, and effects on cell growth occur
anywhere from 3 to 7 days following GSI treatment (32, 43). In
contrast, doxycycline specifically inhibits Notch1IC expression
and allows temporal comparison of the recruitment of intra-
cellular Notch1 and its coactivators to target gene loci.
Gene expression profiling of this Dox-regulated Notch1IC
T-ALL line demonstrated upregulation of numerous known
Notch1IC target genes, including nrarp, nr2f2, notch3, hes1,
cd25, adam19 (or -meltrin), deltex, il-10, irf-4, egr1, and pre-T
(1, 9, 20). Ingenuity Systems software analysis revealed the
c-Myc pathway as the central pathway (other than Notch1)
induced in the absence of Dox or presence of active Notch1
signaling. c-Myc and 35 known c-Myc target genes (cad, odc1,
nol1, bcat1, srm, and others denoted with an asterisk in Fig. 4)
were induced/repressed in the absence of Dox or presence of
intracellular Notch1. We demonstrate that Notch1IC mediates
leukemic growth by inducing c-myc expression since retroviral
expression of c-myc rescues the growth arrest/apoptosis in-
duced upon GSI treatment of multiple mouse tal1 leukemic
lines. In our RIM screen, proviral insertions were also ob-
FIG. 6. Dox-dependent recruitment of Notch1IC and MAM to the
hes1 and c-myc promoters. (A) ChIP assay for CSL, Notch1IC, MAM,
RNA polymerase II (Pol II), CDK9, and acetylated histones H3 and
H4. Briefly, the Dox-dependent 3404 leukemic cell line was grown in
RPMI medium with 10% fetal bovine serum at 37°C and treated with
doxycycline (2 g/ml) for 48 h (Dox) or left untreated (Dox).
Immunoprecipitations (IPs) were carried out using the respective
monoclonal or polyclonal antibodies or without antibody (No-ab) as a
control. Immunoprecipitated and input DNAs were amplified by PCR
using primers specific for the mouse hes1 promoter (A) or the mouse
c-myc promoter (B and C). PCR-amplified products were analyzed on
2% agarose gels and stained with ethidium bromide.
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served in the c-myc locus (6/25 tumors), suggesting that a
certain threshold level of c-myc expression is essential for in-
duction/maintenance of T-ALL (achieved by either Notch1
activation or direct insertion near c-myc).
Preleukemic studies of mouse models of T-ALL have dem-
onstrated that T-cell oncogenes like tal1 and/or lmo1/2 arrest
thymocyte development (5, 19, 31), and thus activation of
Notch1 and potentially c-myc may occur to rescue develop-
mentally arrested, preleukemic thymocytes. Consistent with
this model, we detected evidence of Notch1 activation and
increased c-myc levels in preleukemic tal1 thymocytes (39),
suggesting that Notch1 mutations are early events in T-cell
leukemogenesis and may reflect a response to differentiation
arrest. Evidence of early Notch1 activation has also been ob-
served in SCL/LMO1 transgenic mice (26). Although c-myc
levels clearly correlate with Notch1 activity in preleukemic or
leukemic stages of disease and retroviral c-myc expression pre-
vents GSI-induced cell cycle arrest (Fig. 5C), it was unclear
whether c-myc activation was a direct or indirect effect of
Notch1 activation. The kinetics of c-myc activation (as compared
to the direct Notch1 target, hes1) suggests that Notch1IC/MAM
complex may directly stimulate c-myc transcription. Consistent
with the direct model, the promoter of the mouse c-myc gene
contains three CSL binding sites (Fig. 6B and C). One of the
three CSL binding sites found in the promoter region is also
conserved in the human c-MYC promoter region, suggesting
that this may also be Notch1 regulated in human T-ALL.
Moreover, increases in hes1 or c-myc mRNA levels were ac-
companied by an enrichment of Notch1IC, Mastermind, and
RNA polymerase II/CDK9 at the promoter regions containing
the CSL binding sites. The increase in c-myc transcriptional
activity was also associated with increases in histone acetyla-
tion. These Dox-dependent changes were specific to the pro-
moter region of c-myc that contained conserved CSL binding
sites and when 3 regions of c-myc were interrogated by ChIP,
no evidence of Notch1IC or MAM binding was observed.
c-myc has also been recently implicated as a Notch1 target
gene in mouse mammary tumorigenesis (22). Mouse mammary
tumor virus (MMTV) LTR-driven expression of Notch1IC in-
duces mammary tumors in female mice, and an absence of
c-myc delays tumor incidence and penetrance. Mammary tu-
mors express increased c-myc mRNA levels, and a Notch1/
Cbf1 complex was shown to bind the c-myc promoter (22).
Thus, our study and that of Klinakis et al. reveal c-myc as a
direct Notch1 target gene in diverse transformed cell types
(i.e., mouse leukemic T cells and mammary tumor cells). Al-
though Klinakis et al. provide genetic evidence that links
Notch1 to c-myc, Notch1IC-induced mammary tumors do
form, albeit with increased latency, in the absence of c-myc
(22). Thus, it remains unclear whether Notch1 target genes
other than c-myc also contribute to mammary tumorigenesis or
whether Myc family members compensate for an absence of
c-myc in the tumors that do form in the MMTV-Notch1IC
“null” Myc mice. For potential therapeutic reasons, it will be
important to test whether mammary tumor growth, like T-cell
leukemic growth, remains Notch1 dependent.
In our study, we provide functional data that demonstrate
that Notch1 supports leukemic growth by maintaining c-myc
mRNA levels. Consistently, primary tumors isolated from tal1
transgenic mice with increased endogenous Notch1 activity
due to deletions in the PEST region (32) exhibit 9- to 23-fold
increases in c-myc mRNA levels (Fig. 5A). Notch1 inhibition
results in three- to fourfold decreases in c-myc mRNA levels
and induction of G1 arrest and apoptosis (Fig. 2 and 5). Thus,
this work identifies c-myc as both a direct and critical target of
Notch1 in T-cell leukemogenesis.
Although c-Myc promotes entry into the cell cycle by in-
creasing E2F1 levels, increased c-Myc and/or E2F1 levels have
been shown to activate the Arf-p53 oncogene checkpoint (11,
46). Consistently, E-myc transgenic mice exhibit apoptosis
and acquire Ink4a/Arf deletions (46). INK4A/ARF losses are
also frequent in human T-ALL and in mouse tal1 tumors (14,
39). Thus, Notch1 mutation may induce and sustain elevated
c-myc levels and thereby provide selective pressure for INK4A/
ARF loss.
A percentage of mouse T-ALL lines exhibit evidence of
Notch1 activation but appear resistant to GSI, suggesting that
additional members of the Notch1 signaling pathway may be
mutated in these tumors. For example, inactivating mutations
in the negative regulators Numb, Itch, or Fbw7/Sel10 or in the
kinases such as CycC:CDK8 (16) which trigger Notch1 ubiq-
uitination could lead to increased Notch1 activation and GSI
resistance. Similarly, mutations in Notch1 coactivators Master-
mind-like 1, 2, and 3 may also contribute to T-ALL. Although
these in vitro studies suggest that GSI may have efficacy in 50%
of human T-ALL patients that harbor mutations in the Notch1
receptor (43), the identification of GSI-resistant mouse and
human T-ALL lines and the implication that Notch1 activation
contributes to mammary tumorigenesis (22) urge the develop-
ment of additional Notch1 pathway therapeutics perhaps
aimed at displacing the intracellular Notch1/MAM complex
from the CSL repressor or potentially directly targeting c-Myc.
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